期刊论文

Huang, Weijin;Hu, Zhongyu;Wang, Qihui

英文

信号转导与靶向治疗

2095-9907

2022

7

1

492-501

10.1038/s41392-022-00874-7

We sincerely thank the laboratories and associated researchers who obtained the original samples and viral sequence information, as well as those who uploaded and shared genomic data through GISAID. These samples and data were critical to this study and were the cornerstone that allowed this study to proceed smoothly. We thank We thank Acro Biosystems Co. for the recombinant S protein of Alpha, Beta, and Gamma; Dr. Jiankai Liu from Shenzhen Kangtai Biological Products Co., Ltd. and Beijing Minhai Biotechnology Co. for providing inactivated vaccine-immunized sera. We thank Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., and Liaoning Mao Kang Yuan Biotech Co. Ltd. for providing recombinant protein vaccine-immunized sera; Xiaowang Qu of the University of South China for convalescence serum samples. This work was supported by the General Program of the National Natural Science Foundation of China (grant number 82073621 & 82172244), National Key Research and Development Program of China (grant number 2021YFC0863300), Beijing Municipal Science and Technology Project (Z211100002521018), and Bill & Melinda Gates Foundation (Investment ID INV-006379). We thank Gillian Campbell, PhD., from Liwen Bianji (Edanz) (www.liwenbianji.cn), for editing the English text of a draft of this manuscript.

本校为其他机构

Emerging SARS-CoV-2 variants are the most serious problem for COVID-19 prophylaxis and treatment. To determine whether the SARS-CoV-2 vaccine strain should be updated following variant emergence like seasonal flu vaccine, the changed degree on antigenicity of SARS-CoV-2 variants and H3N2 flu vaccine strains was compared. The neutralization activities of Alpha, Beta and Gamma variants’ spike protein-immunized sera were analysed against the eight current epidemic variants and 20 possible variants combining the top 10 prevalent RBD mutations base...